Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Omosa Manyonyi, Gloria ^a   Park, Harriet ^b   Mutua, Gaudensia ^a   Farah, Bashir ^a   Bergin, Philip J ^c   Laufer, Dagna ^b   Lehrman, Jennifer ^b   Chinyenze, Kundai ^b   Barin, Burc ^d   Fast, Pat ^b   Gilmour, Jill ^c   Anzala, Omu ^a  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCEPTABILITY; ADULT; ANALYTICAL PARAMETERS; ARTICLE; FEASIBILITY STUDY; FEMALE; HUMAN; INFECTION RISK; KENYA; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MOUTH MUCOSA; MUCUS SECRETION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RECTUM MUCOSA; REFUSAL TO PARTICIPATE; REPEAT PROCEDURE; REPEATED MUCOSAL SPECIMEN COLLECTION; SALIVA; SAMPLER; SAMPLING; SPERM; VAGINA MUCOSA; ADOLESCENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LABORATORY DIAGNOSIS; MUCOSA; PATIENT ATTITUDE; PROCEDURES; PSYCHOLOGY; SPECIES DIFFERENCE; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADOLESCENT; ADULT; AIDS VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; FEASIBILITY STUDIES; FEMALE; HIV-1; HUMANS; KENYA; MALE; MUCOUS MEMBRANE; PATIENT ACCEPTANCE OF HEALTH CARE; SPECIES SPECIFICITY; SPECIMEN HANDLING; YOUNG ADULT;

EID: 84910002455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110228     Document Type: Article

References (17)

1. Hirbod T, Broliden K (2007) Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J Intern Med 262: 44-58.
2. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, et al. (2008) HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 22: 727-735.
3. Haase AT (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217-223.
4. Cummins JE, Jr., Doncel GF (2009) Biomarkers of cervicovaginal inflammation for the assessment of microbicide safety. Sex Transm Dis 36: S84-91.
5. Leroux-Roels G, Maes C, Clement F, van Engelenburg F, van den Dobbelsteen M, et al. (2013) Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS One 8: e55438.
6. Musey L, Ding Y, Elizaga M, Ha R, Celum C, et al. (2003) HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J Immunol 171: 1094-1101.
7. Pialoux G, Hocini H, Perusat S, Silberman B, Salmon-Ceron D, et al. (2008) Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine 26: 2657-2666.
8. Schneider JA, Alam SA, Ackers M, Parekh B, Chen HY, et al. (2007) Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy. J Infect Dis 196: 1637-1644.
9. Kaul R, Ball TB, Hirbod T (2011) Defining the genital immune correlates of protection against HIV acquisition: co-infections and other potential confounders. Sex Transm Infect 87: 125-130.
10. Instead web site. Available: http://softcup.com/how/faqs. Accessed 2014 July14.
11. Hasselrot K, Saberg P, Hirbod T, Soderlund J, Ehnlund M, et al. (2009) Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 23: 329-333.
12. Castle PE, Rodriguez AC, Bowman FP, Herrero R, Schiffman M, et al. (2004) Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. Clin Diagn Lab Immunol 11: 399-405.
13. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM (2005) Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 175: 7560-7567.
14. North BB, Oldham MJ (2011) Preclinical, clinical, and over-the-counter postmarketing experience with a new vaginal cup: menstrual collection. J Womens Health (Larchmt) 20: 303-311.
15. Price CF, Tyssen D, Sonza S, Davie A, Evans S, et al. (2011) SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 6: e24095.
16. Rositch AF, Gatuguta A, Choi RY, Guthrie BL, Mackelprang RD, et al. (2012) Knowledge and acceptability of pap smears, self-sampling and HPV vaccination among adult women in Kenya. PLoS One 7: e40766.
17. Sanders EJ, Okuku HS, Smith AD, Mwangome M, Wahome E, et al. (2013) High HIV-1 incidence, correlates of HIV-1 acquisition, and high viral loads following seroconversion among MSM. AIDS 27: 437-446.